Bull&Bear | Landsea Homes Soars 60.66% Amid Acquisition News, Zhengye Biological Plummets 44.80%

In the realm of bullish stocks, Landsea Homes (LSEA) experienced a significant surge, rising by 60.66% and marking a consecutive five-day increase. Over the past five days, the stock has appreciated by 94.31%. This impressive performance comes in the wake of New Home Company's announcement to acquire Landsea Homes for $1.2 billion.

Bakkt Holdings (BKKT) witnessed an impressive gain of 47.35%. The company's first-quarter earnings per share reached $1.13, a notable improvement from last year's $(1.86). Moreover, Bakkt's revenue increased to $1.07 billion compared to $854.6 million in the previous year.

Humacyte (HUMA) rose by 31.06%, continuing a two-day upward trajectory, with a total increase of 45.38% over the past two days. The company's first-quarter earnings per share exceeded expectations, affirming positive financial performance.

Microvast Holdings (MVST) saw a 30.13% increase, marking a consecutive five-day upward trend. The stock has risen by 61.98% in the past five days, driven by strong financial results and technological advancements that bolster a buy rating.

FatPipe (FATN) increased by 28.27%. The company plans to hire 12 regional sales managers in the U.S. to support its growth strategy in SD-WAN, SASE, and network security concepts.

Turning to bearish stocks, Zhengye Biological (ZYBT) plummeted by 44.80%. Zhengye's sharp decline is noteworthy, especially considering its product portfolio that spans vaccines for pigs, poultry, cattle, sheep, and pets.

Renegenix (RGC) fell by 33.58%. A statement from AIP Electronics clarified that it has no association with the U.S.-listed company Renegenix.

NetClass Technology (NTCL) decreased by 30.08%, as the company faced a trading suspension due to volatility.

3D Systems (DDD) dropped by 26.67%. The stock's decline was partly attributed to the alleviation of tariff concerns, which impacted first-quarter expenditures.

Halozyme Therapeutics (HALO) experienced a 24.56% decrease following Leerink Partners' downgrade to underperform, with a set target price of $47.